Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study.

Shen, Xia-Bo; Li, Guang-Liang; Zheng, Ya-Bing; Chen, Zhan-Hong; Cao, Wen-Ming; Wang, Xiao-Jia; Shao, Xi-Ying

Shen, Xia-Bo; Li, Guang-Liang; Zheng, Ya-Bing; Chen, Zhan-Hong; Cao, Wen-Ming; Wang, Xiao-Jia; Shao, Xi-Ying.

Afiliación

Shen XB; Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Li GL; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Zheng YB; Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Chen ZH; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Cao WM; Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Wang XJ; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Shao XY; Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.

Ann Transl Med ; 9(16): 1334, 2021 Aug.

Article en En | MEDLINE | ID: mdl-34532471

Palabras clave

Advanced breast cancer (ABC); aromatase inhibitors (AIs); everolimus (EVE); fulvestrant (FUL); retrospective study

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Transl Med Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google